|
Ordering of RSV products in the IIS is open as of today, October 8th. We are still asking providers to advertise excess doses and for providers in need of product to regularly check the advertisements before placing an order. There are still small pockets across the state with excess doses and we need to minimize waste as much as possible.
RSV Ordering Guidance and Reminders
- Nirsevimab (Beyfortus) is the only product available at this time. It can be ordered in a minimum quantity of 5 doses.
- Clesrovimab (Enflosia) will not be available for ordering until December. It can be orderd in a minimum quantity of 1 dose package of a 10-dose package.
- Orders of the nirsevimab 50mg product will be prioritized for birthing hospitals and limited to minimum amounts for other providers
- If there is not enough vaccine in allocation, orders will be reduced based on equity framework and allocation percentage received
Ordering Schedule
- Orders will be processed weekly on Wednesdays
- Orders must be in “Pending State Approval” status in the IIS by close of business Tuesday
- Please allow at least 3 days for accountability checks and order approval.
-
Flexible ordering: Respiratory product orders can be placed anytime and as often as needed.
Ordering Caps
- Abrysvo - vaccine for pregnant people under age 19
- Order in quantities of 1 and only order if you have an eligible patient (32-36 weeks gestation between now and January 31st, 2026)
- Order requests need to be made via email to WAChildhoodVaccines@doh.wa.gov. Please confirm in your email that your clinic has a pregnant patient eligible for the vaccine.
- Nirsevimab and clesrovimab - monocloncal antibody
- Individual orders will be approved for up to 50% of the doses administered in the same month last year.
- New providers or those without prior administration data will be capped at 50 doses.
- If supply is limited, orders will be reduced based on the Vaccine Allocation Plan.
- Orders will be denied if providers already have a 30-day supply of product on hand.
- If provider choose to change RSV product when available, no orders will be approved for new product until existing supply is at a 2-week supply.
- No orders will be approved if there is existing inventory on hand with these quantities
- Order caps are in effect until usage demonstrates larger quantities are needed
- Approvals are based on provider's publicly funded doses reported in the IIS -- if your site has data quality errors you may not get the amount requested
Great news! The CDC has officially opened COVID-19 vaccine ordering for the 2025–2026 season. Pre-orders that were pending state approval were to CDC on Monday and Tuesday. Nearly 18,000 doses of CVP COVID-19 vaccine for children is on its way to Washington! Thank you for your patience.
Vaccine Ordering Guidance and Reminders
- Choose one brand of COVID-19 vaccine per age group.
- All vaccines will appear in your order set, but you must select only one product for each age range.
- Refer to the 2025–2026 State-Supplied COVID-19 Vaccines At-A-Glance guide to determine the best product for your facility.
- Providers enrolled in the WA State Childhood Vaccine Program are required to carry and offer COVID-19 vaccines for the population they serve. We expect all providers to have COVID-19 vaccine available.
- Ordering schedule:
- Initially, orders will be processed weekly on Thursdays. Daily processing will occur once sufficient supply is available.
- Orders must be in “Pending State Approval” status in the IIS by close of business Wednesday.
- Please allow at least 3 days for accountability checks and order approval.
- Individual order limits:
- Orders will be approved for up to 50% of the doses administered in the same month last year.
- New providers or those without prior administration data will be capped at 50 doses.
- If supply is limited, orders will be reduced based on the Vaccine Allocation Plan.
-
Flexible ordering: Respiratory product orders can be placed anytime and as often as needed.
-
Best practices:
- 4–6 weeks for Pfizer and Moderna
- 2 weeks for Sanofi/Novavax
- Place smaller, more frequent orders to reduce waste.
- Order only what can be used within:
Shelf Life and Storage Expectations
- Moderna: Initial dating 3–6 months; may shorten as the season progresses.
- Pfizer:
- 12y+ doses: Refrigerated, ≥12 weeks shelf life.
- 5–11y doses: Ultracold, ≥3 months shelf life (when stored ultracold).
- Shelf life may be shorter later in the season.
- Sanofi/Novavax: Expiry December 31, 2025. Sanofi is working with FDA on a shelf-life extension.
Helpful Resources
Thank you for your patience and continued partnership in protecting Washington communities from respiratory diseases. Your work is essential to ensuring equitable access to vaccines across our state.
Join us for the next CVP Training Series on Thursday, October 16th. This session will focus on CVP updates related to the current respiratory season as well as training on storage and handling requirements for COVID-19 vaccine products.
Date: October 16, 2025
Time: Noon – 1:00 p.m. PDT
Primary Audience: Providers, vaccine coordinators and staff that order for the Childhood Vaccine Program
The Washington State Department of Health (DOH) is excited to announce the launch of a new Respiratory Immunization Dashboard.
Developed by DOH’s Office of Immunization Assessment and Informatics team, this updated, public-facing dashboard brings together immunization data for influenza (flu), COVID-19, and respiratory syncytial virus (RSV) - both pediatric and adult - into one centralized location for the first time.
This new tool makes it easier for public health professionals, healthcare partners, policymakers, and the public to access and understand immunization coverage across Washington state. Users will be able to view:
- Geographic and demographic coverage rates for each respiratory immunization
- Statewide total doses administered
- Trends over time in immunization uptake
With the launch of this dashboard, the separate COVID-19, Influenza, and Respiratory Illness Immunization dashboards currently in use will be retired. The immunization section of the Respiratory Illness Data Dashboard | Washington State Department of Health will now redirect users to this new, consolidated dashboard.
Key Data Highlights:
- Flu and COVID-19 vaccine uptake has declined over the past three seasons.
- Last season approximately 30% of people aged 6 months and older received a dose of flu vaccine. Currently, flu vaccine administration is lagging behind last season with 18% fewer doses having been administered.
- Approximately 18.5% of people aged 6 months and older received a dose of COVID-19 vaccine last season. So far this season, 36% fewer doses of COVID-19 vaccine are being administered compared to the same point last season.
- Last season 41.3% of infants 0-7 months received an RSV immunization.
- So far this season, the number of RSV doses administered to infants is outpacing administration at the same point last season.
- Over 540,000 doses of RSV vaccine have been administered to Washingtonians over the age of 18 since August 2023.
- Statewide, RSV coverage in adults over 75 years continues to increase. Currently, over 40% of adults over 75 are up to date on their RSV vaccine.
We hope this new dashboard will improve data transparency, support immunization surveillance, and make it easier for everyone — from local health jurisdictions to healthcare providers to Washington residents — to stay informed and protected during respiratory virus season.
“With respiratory virus season upon us, vaccines remain the best protection against serious illness from COVID-19, flu, and RSV,” said Jamilia Sherls, Director, Office of Immunization. “This new dashboard gives Washington residents a clear view of vaccination trends and coverage; we encourage everyone to get updated vaccines. Our recommendations protect those most at risk, including young children, older adults, people who are pregnant, those living in group settings, and anyone who lives or works with vulnerable people.”
If you have questions, please contact the Assessment and Informatics team at WAIISDataRequests@doh.wa.gov
RSV monoclonal antibodies for infants should generally begin on October 1 and continue through March 31 in most of the United States. Here’s a summary of the recommendations:
- Administer nirsevimab (Beyfortus) or clesrovimab (ENFLONSIA) to infants younger than age 8 months and 0 days whose mothers were not vaccinated against RSV during pregnancy. Infants whose mothers were vaccinated against RSV and those who received a dose of Beyfortus late last season should not receive a dose of RSV preventive antibody now, even if they are still younger than age 8 months.
- A dose of Beyfortus is also recommended for certain children at high risk of severe RSV disease age 8 months through 19 months entering their second RSV season, regardless of their history of maternal vaccination or receipt of a preventive antibody during their first RSV season. Clesrovimab is NOT recommended for children older than 8 months. These high-risk children include American Indian and Alaska Native children (particularly those living in remote areas and with limited access to medical services), children with chronic lung disease of prematurity, severe immunocompromise, and cystic fibrosis with growth under 10th percentile.
- Infant RSV antibody products can be administered at the same time as other routine childhood vaccines. No interval between RSV antibodies and live vaccines (such as MMR and varicella) is necessary.
- Synagis is no longer recommended for use by AAP and the product is being discontinued in December 2025.
 Refer to the American Academy of Pediatrics' (AAP) RSV Immunization Administration Algorithm for more details.
 CDC also developed an infographic to make it easier for clinical staff to determine which RSV prevention measures are recommended at which times of the year.
 Additional Resources
AAP’s recommended Child and Adolescent Immunization Schedule is the best resource for COVID-19 routine vaccination guidelines and vaccination of persons who are immunocompromised. Additional helpful AAP COVID-19 resources include:
WithinReach, in collaboration with the Washington State Department of Health and the Immunization Action Coalition of Washington, is excited to announce the 2026 Washington State Immunization Summit, taking place on Thursday, March 19, 2026. This full-day event, hosted by WithinReach, will bring together public health professionals, healthcare providers, community leaders, and advocates to advance immunization efforts across Washington State. Save the date now and stay tuned for registration details coming soon!
Did you know that CVP enrolled providers are not required to keep RSV vaccine products on hand? It's true! At this time, we are not requiring or recommending that providers keep RSV vaccine products in their inventories if it is not routinely administered.
Merck's RSV product, clesrovimab (brand name Enflonsia) will be available in a single dose presentation and has a longer shelf-life than nirsevimab so this product may be a better fit for smaller providers who only need a few doses. Stay tuned to the Vaccine Blurbs for more on this product as it is not yet available to order.
If you are in need of RSV vaccine, please check the Vaccine Advertisements in the IIS or email WAChildhoodVaccines@doh.wa.gov and we will help you locate product in your region. If have product in your inventory that expires later in the season, please consider accepting a transfer of the short dated product to help ensure it gets used.
|
